{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:08:07Z","timestamp":1790813287443,"version":"4.1.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Stereotactic body radiation therapy (SBRT) delivers curative-intent radiation to patients with early-stage non-small cell lung cancer and inoperable thoracic lesions. With improved techniques in tumor delineation, motion management, and delivery of radiation treatments, the therapeutic window within the thorax is able to be maximized. Ongoing technological advances enable highly targeted ablative radiation therapy while sparing adjacent sensitive organs at risk. Further applications of SBRT with combinatorial immunotherapy, the usage of particle therapy, and for patients with more advanced stages of lung cancer and other histologies mark exciting possibilities for the role of SBRT within the thorax.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000753","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:00:09Z","timestamp":1732525209000},"page":"401-406","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Advances in Stereotactic Body Radiation Therapy for Lung Cancer"],"prefix":"10.1097","volume":"30","author":[{"given":"Katie N.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250928","first-page":"32","article-title":"Medically inoperable stage I non\u2013small cell lung cancer: best practices and long-term outcomes","volume":"8","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"bib2-20250928","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","article-title":"Segmentectomy versus lobectomy in small-sized peripheral non\u2013small-cell lung cancer (JCOG0802\/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"bib3-20250928","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non\u2013small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib4-20250928","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaoncol.2023.7269","article-title":"Stereotactic radiation therapy in early non\u2013small cell lung cancer and interstitial lung disease: a nonrandomized clinical trial","volume":"10","year":"2024","journal-title":"JAMA Oncol"},{"key":"bib5-20250928","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/JTO.0000000000000524","article-title":"Stereotactic ablative radiation therapy for the treatment of early-stage non\u2013small-cell lung cancer: CEPO review and recommendations","volume":"10","year":"2015","journal-title":"J Thorac Oncol"},{"key":"bib6-20250928","doi-asserted-by":"crossref","first-page":"104","DOI":"10.21037\/atm-21-6256","article-title":"Comparison of stereotactic body radiotherapy and radiofrequency ablation for early-stage non\u2013small cell lung cancer: a systematic review and meta-analysis","volume":"10","year":"2022","journal-title":"Ann Transl Med"},{"key":"bib7-20250928","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.ijrobp.2009.07.1751","article-title":"Stereotactic body radiotherapy (SBRT) for operable stage I non\u2013small-cell lung cancer: can SBRT be comparable to surgery?","volume":"81","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib8-20250928","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2018.1251","article-title":"Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG Oncology RTOG 0618 trial","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib9-20250928","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non\u2013small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib10-20250928","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S1470-2045(21)00401-0","article-title":"Stereotactic ablative radiotherapy for operable stage I non\u2013small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"bib11-20250928","article-title":"Centralized quality assurance of stereotactic body radiation therapy for the Veterans Affairs Cooperative Studies program study number 2005: a phase 3 randomized trial of lung cancer surgery or stereotactic radiotherapy for operable early-stage non\u2013small cell lung cancer (VALOR)","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"7 Suppl 3","key":"bib12-20250928","first-page":"S94","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non\u2013small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study","volume":"2","year":"2007","journal-title":"J Thorac Oncol"},{"key":"bib13-20250928","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ijrobp.2005.03.073","article-title":"Stereotactic body radiation therapy of early-stage non\u2013small-cell lung carcinoma: phase I study","volume":"63","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib14-20250928","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2023.03.056","article-title":"Some like it hot: the value of dose and hot spots in lung stereotactic body radiation therapy","volume":"117","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib15-20250928","first-page":"14(15)","article-title":"Relationship between dose prescription methods and local control rate in stereotactic body radiotherapy for early stage non\u2013small-cell lung cancer: systematic review and meta-analysis","volume":"14","year":"2022","journal-title":"Cancers (Basel)"},{"key":"bib16-20250928","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib17-20250928","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","year":"2010","journal-title":"JAMA"},{"key":"bib18-20250928","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.adro.2019.01.002","article-title":"Long-term clinical outcomes and safety profile of SBRT for centrally located NSCLC","volume":"4","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"bib19-20250928","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG Oncology\/RTOG 0813 trial","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib20-20250928","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ijrobp.2014.01.022","article-title":"Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non\u2013small cell lung cancer: how to fly in a \u201cno fly zone\u201d","volume":"88","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib21-20250928","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.radonc.2021.03.001","article-title":"Ablative radiotherapy for ultracentral lung cancers: dosimetric, geometric, and volumetric predictors of outcomes and toxicity","volume":"158","year":"2021","journal-title":"Radiother Oncol"},{"key":"bib22-20250928","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial\u2014a prospective Nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","year":"2021","journal-title":"J Thorac Oncol"},{"key":"bib23-20250928","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2024.03.050","article-title":"Stereotactic radiation for ultra-central non\u2013small cell lung cancer: a safety and efficacy trial (SUNSET)","volume":"120","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib24-20250928","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ijrobp.2019.03.035","article-title":"Role of on-table plan adaptation in MR-guided ablative radiation therapy for central lung tumors","volume":"104","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib25-20250928","first-page":"201","article-title":"Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: results of a phase 1 trial","volume":"4","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"bib26-20250928","doi-asserted-by":"crossref","first-page":"110034","DOI":"10.1016\/j.radonc.2023.110034","article-title":"Widening the therapeutic window for central and ultra-central thoracic oligometastatic disease with stereotactic MR-guided adaptive radiation therapy (SMART)","volume":"190","year":"2024","journal-title":"Radiother Oncol"},{"key":"bib27-20250928","first-page":"100488","article-title":"Magnetic resonance-guided stereotactic body radiation therapy\/hypofractionated radiation therapy for metastatic and primary central and ultracentral lung lesions","volume":"4","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"bib28-20250928","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2024.02.054","article-title":"Adapt or perish: adaptive RT for NSCLC","volume":"119","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib29-20250928","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13014-022-02070-x","article-title":"Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3)","volume":"17","year":"2022","journal-title":"Radiat Oncol"},{"key":"bib30-20250928","doi-asserted-by":"crossref","first-page":"e14375","DOI":"10.1002\/acm2.14375","article-title":"Beyond conventional bounds: surpassing system limits for stereotactic ablative (SAbR) lung radiotherapy using CBCT-based adaptive planning system","volume":"25","year":"2024","journal-title":"J Appl Clin Med Phys"},{"key":"bib31-20250928","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.radonc.2010.09.006","article-title":"Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: a dosimetric comparison with photon-based stereotactic body radiotherapy","volume":"97","year":"2010","journal-title":"Radiother Oncol"},{"key":"bib32-20250928","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7785\/tcrt.2012.500208","article-title":"Protons safely allow coverage of high-risk nodes for patients with regionally advanced non\u2013small-cell lung cancer","volume":"10","year":"2011","journal-title":"Technol Cancer Res Treat"},{"key":"bib33-20250928","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ijrobp.2010.03.012","article-title":"Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non\u2013small-cell lung cancer","volume":"80","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib34-20250928","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijrobp.2011.05.062","article-title":"Treatment of non\u2013small cell lung cancer patients with proton beam-based stereotactic body radiotherapy: dosimetric comparison with photon plans highlights importance of range uncertainty","volume":"83","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib35-20250928","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ijrobp.2018.02.022","article-title":"Phase 2 study of stereotactic body radiation therapy and stereotactic body proton therapy for high-risk, medically inoperable, early-stage non\u2013small cell lung cancer","volume":"101","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib36-20250928","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/jrr\/rrw041","article-title":"Dosimetric comparison of carbon ion and x-ray radiotherapy for stage IIIA non\u2013small cell lung cancer","volume":"57","year":"2016","journal-title":"J Radiat Res"},{"key":"bib37-20250928","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fonc.2020.00082","article-title":"Carbon ion therapy: a modern review of an emerging technology","volume":"10","year":"2020","journal-title":"Front Oncol"},{"key":"bib38-20250928","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/JTO.0b013e3181560a68","article-title":"Carbon ion radiotherapy for stage I non\u2013small cell lung cancer using a regimen of four fractions during 1 week","volume":"2","year":"2007","journal-title":"J Thorac Oncol"},{"key":"bib39-20250928","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jtho.2016.12.012","article-title":"A dose escalation clinical trial of single-fraction carbon ion radiotherapy for peripheral stage I non\u2013small cell lung cancer","volume":"12","year":"2017","journal-title":"J Thorac Oncol"},{"key":"bib40-20250928","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.radonc.2017.05.007","article-title":"Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non\u2013small cell lung cancer: a systematic review and hypothesis-generating meta-analysis","volume":"123","year":"2017","journal-title":"Radiother Oncol"},{"key":"bib41-20250928","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1038\/s41467-023-40813-w","article-title":"Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non\u2013small cell lung cancer: a multi-institutional phase I trial","volume":"14","year":"2023","journal-title":"Nat Commun"},{"key":"bib42-20250928","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijrobp.2023.03.069","article-title":"Safety and efficacy results from iSABR, a phase 1 study of stereotactic ABlative radiotherapy in combination with durvalumab for early-stage medically inoperable non\u2013small cell lung cancer","volume":"117","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib43-20250928","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non\u2013small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"bib44-20250928","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jamaoncol.2024.1527","article-title":"Radiation with immunotherapy may be a double-edged sword\u2014how can we learn from recent negative clinical trials?","volume":"10","year":"2024","journal-title":"JAMA Oncol"},{"key":"bib45-20250928","doi-asserted-by":"crossref","first-page":"S630","DOI":"10.1016\/j.jtho.2019.08.1328","article-title":"P1.18-12 PACIFIC-4\/RTOG 3515: phase III study of durvalumab following SBRT for unresected stage I\/II, lymph-node negative NSCLC","volume":"14","year":"2019","journal-title":"J Thorac Oncol"},{"key":"bib46-20250928","article-title":"Radiotherapy in lung cancer: ally or foe of immunotherapy?","volume":"11","year":"2023","journal-title":"Med Res Arch"},{"key":"bib47-20250928","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/OP.22.00475","article-title":"Stereotactic body radiotherapy for the management of early-stage non\u2013small-cell lung cancer: a clinical overview","volume":"19","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"bib48-20250928","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/j.ijrobp.2022.07.1516","article-title":"KEYNOTE-867: phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non\u2013small-cell lung cancer (NSCLC)","volume":"114","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib49-20250928","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13014-015-0340-9","article-title":"Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules","volume":"10","year":"2015","journal-title":"Radiat Oncol"},{"key":"bib50-20250928","doi-asserted-by":"crossref","first-page":"101284","DOI":"10.1016\/j.adro.2023.101284","article-title":"Clinical and dosimetric risk factors associated with radiation-induced lung toxicities after multiple courses of lung stereotactic body radiation therapy","volume":"9","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"bib51-20250928","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13014-023-02286-5","article-title":"Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer","volume":"18","year":"2023","journal-title":"Radiat Oncol"},{"key":"bib52-20250928","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jtho.2017.02.018","article-title":"Long-term outcomes of salvage stereotactic ablative radiotherapy for isolated lung recurrence of non\u2013small cell lung cancer: a phase II clinical trial","volume":"12","year":"2017","journal-title":"J Thorac Oncol"},{"key":"bib53-20250928","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ijrobp.2016.08.032","article-title":"Stereotactic body radiation therapy boost after concurrent chemoradiation for locally advanced non\u2013small cell lung cancer: a phase 1 dose escalation study","volume":"96","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib54-20250928","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jtho.2017.07.036","article-title":"Concomitant chemotherapy and radiotherapy with SBRT boost for unresectable stage III non\u2013small cell lung cancer: a phase I study","volume":"12","year":"2017","journal-title":"J Thorac Oncol"},{"key":"bib55-20250928","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ijrobp.2012.11.011","article-title":"Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non\u2013small cell lung cancer: a prospective study","volume":"85","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib56-20250928","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1748-717X-8-179","article-title":"Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer","volume":"8","year":"2013","journal-title":"Radiat Oncol"},{"key":"bib57-20250928","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamaoncol.2023.6033","article-title":"Accelerated hypofractionated chemoradiation followed by stereotactic ablative radiotherapy boost for locally advanced, unresectable non\u2013small cell lung cancer: a nonrandomized controlled trial","volume":"10","year":"2024","journal-title":"JAMA Oncol"},{"key":"bib58-20250928","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.prro.2023.04.014","article-title":"Full dose SBRT in combination with mediastinal chemoradiation for locally advanced, non\u2013small cell lung cancer: a practical guide for planning, dosimetric results from a phase 2 study, and a treatment planning guide for the phase 3 NRG Oncology LU-008 trial","volume":"13","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"bib59-20250928","article-title":"Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non\u2013small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial","year":"2024","journal-title":"Lancet Respir Med"},{"key":"bib60-20250928","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s11912-023-01473-7","article-title":"Immune priming with spatially fractionated radiation therapy","volume":"25","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"bib61-20250928","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijrobp.2016.10.041","article-title":"Multi-institutional experience of stereotactic ablative radiation therapy for stage I small cell lung cancer","volume":"97","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib62-20250928","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1200\/JCO.20.03364","article-title":"Radiation therapy for small-cell lung cancer: ASCO guideline endorsement of an ASTRO guideline","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib63-20250928","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.prro.2020.02.009","article-title":"Radiation therapy for small cell lung cancer: an ASTRO clinical practice guideline","volume":"10","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"bib64-20250928","first-page":"S1525-7304(24)00159-1","article-title":"DARES: a phase II trial of durvalumab and ablative radiation in extensive-stage small cell lung cancer","year":"2024","journal-title":"Clin Lung Cancer"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:00:44Z","timestamp":1759039244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000753","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}